Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

BeiGene commences dosing in Phase II trial of BGB-A317 to treat urothelial cancer

Go Top